Patritumab deruxtecan's BLA withdrawal was due to HERTHENA-Lung02 trial's unsatisfactory overall survival results, despite progression-free survival significance. The HERTHENA-Lung02 trial compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results